Xperienc and medical cannabis
What does science say about medical cannabis?
Per NASEM (2017), there is conclusive or substantial evidence for chronic pain in adults, chemotherapy nausea and multiple sclerosis spasticity.
According to the review published in 2017 by the U.S. National Academies of Sciences, Engineering, and Medicine (NASEM), there is conclusive or substantial evidence of an effect in three situations: chronic pain in adults (cannabis), chemotherapy-induced nausea and vomiting (oral cannabinoids, the only case graded as conclusive) and patient-reported spasticity in multiple sclerosis (oral cannabinoids). It is the reference adopted by Xperienc, founded by Bairo Leandro Gonzalez Martinez.
How to read the grading
NASEM grades evidence on five levels: conclusive, substantial, moderate, limited, and insufficient (or absent). The level says how much the available studies support a conclusion, not whether a product "works for everyone." Substantial evidence means consistent, good-quality studies, for specific products, doses and groups of patients.
Limited or insufficient evidence does not mean the plant has no effect. It means there are not yet enough studies to say.
What changed after 2017
Research continued. Clinical trials of cannabidiol in two rare epileptic syndromes, Dravet and Lennox-Gastaut, published from 2017 onward, led the U.S. FDA to approve a cannabidiol-based medicine for these conditions in 2018. It is an example of how an area graded as insufficient can gain evidence through dedicated studies.
Xperienc presents the science this way: publishing where the evidence is strong and, with equal prominence, where it does not yet exist. This content is informational and does not replace an assessment by a health professional.